Ophthalmology · 2008
The effect of topical bevacizumab on corneal neovascularization.
Клинический случайКлиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Sang Woo, Ha Byung Jin, Kim Eung Kweon, Tchah Hungwon, Kim Tae-im
Аннотация
PURPOSE: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months.
DESIGN: Prospective, nonrandomized, masked observational case series.
PARTICIPANTS: Ten eyes of 7 patients with corneal NV.
METHODS: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry.
MAIN OUTCOME MEASURES: Corneal NV and changes in ophthalmic evaluations.
RESULTS: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment.
CONCLUSIONS: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.
DESIGN: Prospective, nonrandomized, masked observational case series.
PARTICIPANTS: Ten eyes of 7 patients with corneal NV.
METHODS: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry.
MAIN OUTCOME MEASURES: Corneal NV and changes in ophthalmic evaluations.
RESULTS: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment.
CONCLUSIONS: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.
Предметные рубрики MeSH
Administration, TopicalAdolescentAdultAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabCorneal NeovascularizationEpithelium, CornealFemaleHumansIntraocular PressureMaleMiddle AgedPrognosisProspective StudiesTonometry, OcularVascular Endothelial Growth Factor AVisual Acuity